000856099 000__ 06765cam\a2200529Ii\4500
000856099 001__ 856099
000856099 005__ 20230306145115.0
000856099 006__ m\\\\\o\\d\\\\\\\\
000856099 007__ cr\un\nnnunnun
000856099 008__ 180409s2018\\\\sz\\\\\\o\\\\\001\0\eng\d
000856099 019__ $$a1033660266$$a1034552232$$a1048177764$$a1059187362$$a1066460248$$a1066650891
000856099 020__ $$a9783319764962$$q(electronic book)
000856099 020__ $$a3319764969$$q(electronic book)
000856099 020__ $$a3319764950
000856099 020__ $$a9783319764955
000856099 020__ $$z9783319764955
000856099 0247_ $$a10.1007/978-3-319-76496-2$$2doi
000856099 035__ $$aSP(OCoLC)on1030892176
000856099 035__ $$aSP(OCoLC)1030892176$$z(OCoLC)1033660266$$z(OCoLC)1034552232$$z(OCoLC)1048177764$$z(OCoLC)1059187362$$z(OCoLC)1066460248$$z(OCoLC)1066650891
000856099 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dEBLCP$$dOCLCF$$dUPM$$dOCLCQ$$dCOO$$dVT2$$dCNCEN$$dWYU$$dOCLCQ
000856099 049__ $$aISEA
000856099 050_4 $$aRC924.5.L85
000856099 08204 $$a616.7/72$$223
000856099 24500 $$aNeuropsychiatric systemic lupus erythematosus :$$bpathogenesis, clinical aspects and treatment /$$cShunsei Hirohata, editor.
000856099 264_1 $$aCham, Switzerland :$$bSpringer,$$c2018.
000856099 300__ $$a1 online resource
000856099 336__ $$atext$$btxt$$2rdacontent
000856099 337__ $$acomputer$$bc$$2rdamedia
000856099 338__ $$aonline resource$$bcr$$2rdacarrier
000856099 347__ $$atext file$$bPDF$$2rda
000856099 500__ $$aIncludes index.
000856099 5050_ $$aIntro; Preface; Contents; Chapter 1: Epidemiology of Neuropsychiatric Systemic Lupus Erythematosus; 1.1 Introduction; 1.2 Classification; 1.3 Demographic Features of NPSLE; 1.3.1 Prevalence; 1.3.2 Age of Onset and Ethnicity; 1.3.3 Risk Factors; 1.4 The Limitations of 1999 ACR Nomenclatures and Definitions; 1.5 NPSLE in Childhood; 1.6 Steroid Induced Psychosis; 1.7 Mortality; 1.8 Emerging Problems from the Epidemiological Studies; 1.9 Summary; References; Chapter 2: Genetics; 2.1 Introduction; 2.2 Genetics of Overall SLE; 2.2.1 Major Histocompatibility Complex (MHC) Region.
000856099 5058_ $$a2.2.2 Type I Interferon Pathway and Nucleic Acid Response Genes2.2.3 Defective Clearance of Dying Cell Nucleic Acids; 2.2.4 Signaling Molecules in Immune System Cells; 2.3 Genetics of Neuropsychiatric SLE; 2.3.1 TREX1; 2.3.2 Other Candidate Genes; 2.4 Summary; References; Chapter 3: Immunopathology of Neuropsychiatric Systemic Lupus Erythematosus; 3.1 Introduction; 3.2 Autoantibodies Implicated in the Pathogenesis of NPSLE; 3.2.1 Anti-Phospholipid Antibodies; 3.2.2 Anti-Ribosomal P Antibodies; 3.2.3 Anti-NMDA Receptor NR2 Subunit Antibodies; 3.2.4 Anti-Sm Antibodies.
000856099 5058_ $$a3.2.5 Anti-Neuronal Antibodies3.2.6 Other Autoantibodies; 3.3 Intrathecal Ig Production and Blood-Brain Barrier Damages in NPSLE; 3.3.1 Intrathecal Ig Production; 3.3.2 Blood-Brain Barrier Damages in NPSLE; 3.4 Roles of Complements and Microglia in the Pathogenesis of NPSLE; 3.4.1 Complements; 3.4.2 Microglia; 3.5 Summary; References; Chapter 4: Pathology of Neuropsychiatric Systemic Lupus Erythematosus; 4.1 Introduction; 4.2 Overall Characteristic Features in Pathology in NPSLE; 4.3 The Pathogenesis of Vasculopathy in NPSLE; 4.4 Diffuse Psychiatric/Neuropsychological Syndromes.
000856099 5058_ $$a4.4.1 Acute Confusional State4.4.2 Non-ACS Diffuse NPSLE; 4.5 Neurologic Syndromes; 4.5.1 Cerebrovascular Disease and Reversible Focal Neurological Deficits; 4.5.2 Seizures; 4.5.3 Cranial Neuropathy; 4.5.4 Myelopathy; 4.5.5 Peripheral Neuropathy; 4.6 Other Pathological Features in NPSLE; 4.6.1 Choroid Plexus; 4.6.2 Microglia; 4.6.3 Perivenous Changes; 4.7 Summary; References; Chapter 5: Clinical Features; 5.1 Introduction; 5.2 Classification; 5.3 Case Definition and Clinical Significance; 5.3.1 Diffuse Psychiatric/Neuropsychological Syndromes; 5.3.1.1 Acute Confusional State.
000856099 5058_ $$a5.3.1.2 Anxiety Disorder5.3.1.3 Cognitive Dysfunction; 5.3.1.4 Mood Disorder; 5.3.1.5 Psychosis; 5.3.2 Neurologic Syndromes of CNS; 5.3.2.1 Aseptic Meningitis; 5.3.2.2 Cerebrovascular Disease; 5.3.2.3 Demyelinating Syndrome.; 5.3.2.4 Headache; 5.3.2.5 Movement Disorder (Chorea); 5.3.2.6 Myelopathy; 5.3.2.7 Seizures and Seizure Disorders; 5.3.3 Neurologic Syndromes of PNS; 5.3.3.1 Neuropathy, Cranial; 5.3.3.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (Guillain-Barré Syndrome); 5.3.3.3 Autonomic Disorder; 5.3.3.4 Mononeuropathy (Single/Multiplex); 5.3.3.5 Myasthenia Gravis.
000856099 506__ $$aAccess limited to authorized users.
000856099 520__ $$aNeuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most recalcitrant complications of the disease. According to the 1999 ACR nomenclature and case definitions, diffuse psychiatric/neuropsychological syndromes in NPSLE (anxiety disorder, acute confusional state, cognitive dysfunction, mood disorder, psychosis) (diffuse NPSLE) present psychiatric manifestations unlike neurologic syndromes (focal NPSLE) originating from focal CNS lesions, such as cerebrovascular disease, demyelinating syndrome, headache, aseptic meningitis, chorea, seizures and myelopathy. A number of studies have reported that diffuse NPSLE is usually associated with the presence of autoantibodies against neuronal cells in serum as well as in cerebrospinal fluid (CSF). Moreover, IL-6 has been shown to be elevated in CSF of patients with diffuse NPSLE. Recently, it has been demonstrated that the severity of blood-brain barrier damages plays a crucial role in the development of acute confusional state, the severest form of diffuse NPSLE through the accelerated entry of larger amounts of autoantibodies to NMDA receptor subunit NR2 into the CNS. Since the importance of autoantibodies in the NPSLE has been now evident, such an aggressive treatment, especially B cell depleting therapy, would make sense in that it would reduce the levels of pathogenic autoantibodies, leading to a better prognosis of NPSLE. As far as we know, no single book specifically dedicated to NPSLE alone has been published as yet. As mentioned above, NPSLE constitutes a vastly expanding field of research with increasing numbers of papers published annually. Therefore, we believe that an effort to collect and critically review these publications is invaluable. Such an effort will provide an important contribution to basic researchers as well as clinicians working in the field of neurology, rheumatology, psychiatry and internal medicine fields.
000856099 588__ $$aOnline resource; title from PDF title page (viewed April 10, 2018).
000856099 650_0 $$aSystemic lupus erythematosus.
000856099 650_0 $$aNeurobehavioral disorders.
000856099 7001_ $$aHirohata, Shunsei,$$eeditor.
000856099 77608 $$iPrint version: $$z9783319764955
000856099 852__ $$bebk
000856099 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-76496-2$$zOnline Access$$91397441.1
000856099 909CO $$ooai:library.usi.edu:856099$$pGLOBAL_SET
000856099 980__ $$aEBOOK
000856099 980__ $$aBIB
000856099 982__ $$aEbook
000856099 983__ $$aOnline
000856099 994__ $$a92$$bISE